VANCOUVER, BC / ACCESS Newswire / March 31, 2025 / Verisante Technology, Inc. (TSXV:VER.H) ("Verisante") announces that on March 28, 2025, it mutually agreed with SunRegen Healthcare AG ("SunRegen") to terminate the Letter of Intent ("LOI") dated August 12, 2024, to acquire SunRegen Healthcare AG ("SunRegen"), by way of a Reverse Takeover ("RTO").
Verisante's common shares were previously halted from trading in connection with a proposed RTO with SunRegen Healthcare AG. Trading of the shares on the TSX Venture Exchange is expected to resume on or about two business days after the date on which the Exchange issues a bulletin confirming resumption of trading.
Annual General Meeting
Verisante will be holding an AGM on Thursday, June 12, 2025, with a record date of April 28, 2025. A notice of meeting and record date will be filed on SEDAR+ on April 3, 2025.
About Verisante
Verisante does not currently operate any active business other than to identify and complete a Reverse Takeover (RTO) with a company in one of its target sectors that demonstrates significant growth potential and/or value creation opportunities for shareholders. While the Company may pursue a target in any industry, we intend to focus our search on companies that meet our acquisition target characteristics within the life sciences sectors.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company Contact:
Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 716-5133
Email: info@verisante.com
Forward Looking Statements: This news release may contain forward-looking statements, all of which are subject to market risks, and the possibility that the Company will not be able to achieve all of its stated goals. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
SOURCE: Verisante Technology, Inc.
